Mr. Altomari has has served as our Chairman of the Board and Chief Executive Officer since October 2016 and has been a member of our Board of Directors since February 2004. Mr. Altomari served as President and Chief Executive Officer from 2010 to 2016. Previously Mr. Altomari served as Agile's Executive Chairman from 2004 to 2010. From 2003 to 2008, Mr. Altomari held multiple senior management positions at Barrier Therapeutics, Inc., including Chief Commercial Officer, Chief Operating Officer, and Chief Executive Officer. In 2008, in his role as Chief Executive Officer and as a member of Barrier's Board of Directors, Mr. Altomari completed the successful sale of Barrier to Stiefel Laboratories, which was subsequently acquired by GlaxoSmithKline plc. From 1982 to 2003, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson. Mr. Altomari also serves on the Board of Directors of Insmed Inc. He previously served on the Board of Directors of Recro Pharm, Inc. and  Baudax Bio. Mr. Altomari received an M.B.A. from Rider University and his B.S. from Drexel University. He currently serves as a Trustee of Drexel University and is on LeBow College of Business Advisory Board and the Board of the Charles D. Close School of Entrepreneurship at Drexel University.

Mr. Coiante has been our Chief Financial Officer since August of 2023.  He joined the Company from Aprea Therapeutics, Inc. where he served as the Chief Financial Officer from August 2019 until January 2023 and remained as an employee through March 31, 2023. Prior to joining Aprea Therapeutics, Inc., Mr. Coiante served as our Senior Vice President and Chief Financial Officer from 2010 to August 2019. From 2002 to 2010, Mr. Coiante was Vice President of Finance and Treasurer at Medarex, Inc., formerly a NASDAQ listed biotech company that was acquired in 2009 by Bristol Myers Squibb. From 1989 to 2002, Mr. Coiante held management positions of increasing responsibilities at Ernst & Young LLP. Mr. Coiante received a B.S. in Accounting from Villanova University.

Dr. Korner has been our Chief Medical Officer since August 2020. He has served in various leadership positions of increasing responsibility at several global companies focused on female reproductive health, including Solvay Pharmaceuticals, Wyeth Research, Bayer, and Ferring Pharmaceuticals. Dr. Korner has led more than 50 clinical trials that include multiple engagements with the U.S. Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency in Japan, and Health Canada. Most recently Dr. Korner brought his clinical and development acumen to the gene therapy space as a Senior Vice President of Clinical Development & Medical Affairs at Axovant Gene Therapies, Ltd. He currently serves on the Laidlaw Venture Partners Scientific Advisory Board and the Board of Directors of Voltron Therapeutics as an Independent Director. Dr. Korner received his MD from the Stritch School of Medicine at Loyola University and also holds an MBA from the Michael J. Coles College of Business at Kennesaw State University.

Ms. Whelan joined Agile Therapeutics in December 2019. She brings over 35 years of experience in various capacities in the healthcare industry, including finance, sales, marketing, business development, health policy and market access.  Immediately prior to joining Agile Therapeutics, Kimberly worked on Strategic Initiatives at the Health Management Academy, which is a peer learning company that convenes C-Suite executives from the top-100 US Health Systems and industry to work on solving key healthcare challenges.  After beginning her career in public accounting, Kimberly joined the finance team at Johnson & Johnson.  After her experience in finance, she moved to the commercial side of the business where she spent her most of her career in diverse leadership roles, including:  Sales, where she was responsible for delivering results both individually and as a leader;  Marketing, where she was responsible for creating and executing successful pre-launch, launch and post launch marketing strategies within multiple therapeutic areas;  Business Development, where she completed assessments and recommendations for mergers, licensing, and acquisitions that aligned with the therapeutic area strategic plans. Most recently, Kimberly led Market Access efforts, where she developed strategies for product reimbursement and supported key account directors in identifying potential policy issues related to key therapeutic areas of interest and developing long-term strategies to ensure patient access.  She has worked in both the pharmaceutical and medical device businesses in her career.  Ms. Whelan received a B.S. in Computer Science and Accounting from LaSalle University.